Health Trials

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Imaging Study in Metastatic Clear Cell RCC.

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).

Participants needed: 10
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Jul 16, 2026Locations: 1
Eligibility criteria

At least 18 years old at the time of signing the informed consent form (ICF). [+1]

Subjects taking below mentioned medications that cannot be stopped 5 half-lives... [+1]

Read more
Status: Not yet recruiting

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Participants needed: 40
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Jul 16, 2026Locations: 1
Eligibility criteria

Are at least 18 years old at the time of signing the informed consent form (ICF) [+1]

For Women of Childbearing Potential: Are pregnant or breastfeeding

Read more
Status: Recruiting

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Participants needed: 104
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Jun 9, 2026Locations: 9
Eligibility criteria

At least 18 years old at the time of signing the main study informed consent for... [+4]

Prior RPT, including Lu-177. [+7]

Read more
Status: Recruiting

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)

Participants needed: 590
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Apr 13, 2026Locations: 13
Eligibility criteria

Age of at least 18 years at the time of signing the informed consent form (ICF) [+17]

Subjects with fibrolamellar carcinoma, sarcomatoid HCC or combined hepatocellula... [+20]

Read more
Status: Recruiting

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity \[HA\]-DOTATATE.

Participants needed: 338
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Mar 30, 2026Locations: 54
Eligibility criteria

Histologically proven, Grade 1-2 well differentiated, inoperable, advanced GEP-N... [+12]

Read more